REFERENCES
1. Desbois AC, Cacoub P, Saadoun D. Cryoglobulinemia: an update in 2019. Joint Bone Spine 2019;86:707-13.
2. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013;65:1-11.
4. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974;57:775-88.
5. Roccatello D, Saadoun D, Ramos-Casals M, et al. Cryoglobulinaemia. Nat Rev Dis Primers 2018;4:11.
6. Kolopp-Sarda MN, Miossec P. Cryoglobulins: an update on detection, mechanisms and clinical contribution. Autoimmun Rev 2018;17:457-64.
7. Kolopp-Sarda MN, Nombel A, Miossec P. Cryoglobulins today: detection and immunologic characteristics of 1,675 positive samples from 13,439 patients obtained over six years. Arthritis Rheumatol 2019;71:1904-12.
8. Boleto G, Ghillani-Dalbin P, Musset L, et al. Cryoglobulinemia after the era of chronic hepatitis C infection. Semin Arthritis Rheum 2020;50:695-700.
9. Desbois AC, Comarmond C, Saadoun D, Cacoub P. Cryoglobulinemia vasculitis: how to handle. Curr Opin Rheumatol 2017;29:343-7.
10. Terrier B, Marie I, Lacraz A, et al. Non HCV-related infectious cryoglobulinemia vasculitis: results from the french nationwide CryoVas survey and systematic review of the literature. J Autoimmun 2015;65:74-81.
11. Pietrogrande M, De Vita S, Zignego AL, et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev 2011;10:444-54.
12. Quartuccio L, Bortoluzzi A, Scirè CA, et al. Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian study group of cryoglobulinemia (GISC). Clin Rheumatol 2023;42:359-70.
13. Retamozo S, Brito-Zeron P, Bosch X, Stone JH, Ramos-Casals M. Cryoglobulinemic disease. Oncology 2013;27:1098-105.
14. Retamozo S, Díaz-Lagares C, Bosch X, et al. Life-Threatening cryoglobulinemic patients with hepatitis C: clinical description and outcome of 279 patients. Medicine 2013;92:273-84.
15. Ostojic P, Jeremic IR. Managing refractory cryoglobulinemic vasculitis: challenges and solutions. J Inflamm Res 2017;10:49-54.
16. Harel S, Mohr M, Jahn I, et al. Clinico-biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases. Br J Haematol 2015;168:671-8.
17. Sidana S, Rajkumar SV, Dispenzieri A, et al. Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia. Am J Hematol 2017;92:668-73.
18. Terrier B, Karras A, Kahn JE, et al. The spectrum of type I cryoglobulinemia vasculitis: new insights based on 64 cases. Medicine 2013;92:61-8.
19. Fuentes A, Mardones C, Burgos PI. Understanding the cryoglobulinemias. Curr Rheumatol Rep 2019;21:60.
21. Trejo O, Ramos-Casals M, García-Carrasco M, et al. Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine 2001;80:252-62.
22. Néel A, Perrin F, Decaux O, et al. Long-term outcome of monoclonal (type 1) cryoglobulinemia. Am J Hematol 2014;89:156-61.
23. Zhang LL, Cao XX, Shen KN, et al. Clinical characteristics and treatment outcome of type I cryoglobulinemia in Chinese patients: a single-center study of 45 patients. Ann Hematol 2020;99:1735-40.
24. Athanassiou P, Ioakimidis D, Weston J, Georganas K, Kontomerkos T, Davies KA. Type 1 cryoglobulinaemia associated with a thymic tumour: successful treatment with plasma exchange. Br J Rheumatol 1995;34:285-9.
25. Dammacco F, Lauletta G, Vacca A. The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements. Clin Exp Med 2023;23:255-72.
27. Ferri C, Greco F, Longombardo G, et al. Association between hepatitis C virus and mixed cryoglobulinemia [see comment]. Clin Exp Rheumatol 1991;9:621-4.
28. Retamozo S, Gheitasi H, Quartuccio L, et al. Cryoglobulinaemic vasculitis at diagnosis predicts mortality in primary Sjögren syndrome: analysis of 515 patients. Rheumatology 2016;55:1443-51.
29. Quartuccio L, Baldini C, Priori R, et al. GRISS Group. Cryoglobulinemia in Sjögren syndrome: a disease subset that links higher systemic disease activity, autoimmunity, and local B cell proliferation in mucosa-associated lymphoid tissue. J Rheumatol 2017;44:1179-83.
30. Tzioufas AG, Manoussakis MN, Costello R, Silis M, Papadopoulos NM, Moutsopoulos HM. Cryoglobulinemia in autoimmune rheumatic diseases. Evidence of circulating monoclonal cryoglobulins in patients with primary Sjögren's syndrome. Arthritis Rheum 1986;29:1098-104.
31. García-Carrasco M, Ramos-Casals M, Cervera R, et al. Cryoglobulinemia in systemic lupus erythematosus: prevalence and clinical characteristics in a series of 122 patients. Semin Arthritis Rheum 2001;30:366-73.
32. Perlemuter G, Cacoub P, Sbai A, et al. Hepatitis C virus infection in systemic lupus erythematosus: a case-control study. J Rheumatol 2003;30:1473-8.
34. Giuggioli D, Manfredi A, Colaci M, Manzini CU, Antonelli A, Ferri C. Systemic sclerosis and cryoglobulinemia: our experience with overlapping syndrome of scleroderma and severe cryoglobulinemic vasculitis and review of the literature. Autoimmun Rev 2013;12:1058-63.
35. Galli M, Oreni L, Saccardo F, et al. HCV-unrelated cryoglobulinaemic vasculitis: the results of a prospective observational study by the Italian group for the study of cryoglobulinaemias (GISC). Clin Exp Rheumatol 2017;35:67-76.
36. Ferri C, Sebastiani M, Giuggioli D, et al. Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004;33:355-74.
37. Pasquet F, Combarnous F, Macgregor B, et al. Safety and efficacy of rituximab treatment for vasculitis in hepatitis B virus-associated type II cryoglobulinemia: a case report. J Med Case Rep 2012;6:39.
38. Sawabe T, Uenotsuchi T, Imafuku S, Kohno H, Arima J, Horiuchi T. Remission of hepatitis B virus-related vasculitis with lamivudine. Ann Intern Med 2004;140:672-3.
39. Kawakami T, Ooka S, Mizoguchi M, Soma Y, Yamazaki M. Remission of hepatitis B virus-related cryoglobulinemic vasculitis with entecavir. Ann Intern Med 2008;149:911-2.
40. Enomoto M, Nakanishi T, Ishii M, Tamori A, Kawada N. Entecavir to treat hepatitis B-associated cryoglobulinemic vasculitis. Ann Intern Med 2008;149:912-3.
41. Mazzaro C, Bomben R, Visentini M, et al. Hepatitis B virus-infection related cryoglobulinemic vasculitis. Clinical manifestations and the effect of antiviral therapy: a review of the literature. Front Oncol 2023;13:1095780.
42. Mazzaro C, Dal Maso L, Gragnani L, et al. Hepatitis B virus-related cryoglobulinemic vasculitis: review of the literature and long-term follow-up analysis of 18 patients treated with nucleos(t)ide analogues from the Italian study group of cryoglobulinemia (GISC). Viruses 2021;13:1032.
43. Mazzaro C, Dal Maso L, Visentini M, et al. Hepatitis B virus-related cryogobulinemic vasculitis. The role of antiviral nucleot(s)ide analogues: a review. J Intern Med 2019;286:290-8.
44. Scotto G, Cibelli DC, Saracino A, et al. Cryoglobulinemia in subjects with HCV infection alone, HIV infection and HCV/HIV coinfection. J Infect 2006;52:294-9.
45. Lunel F, Musset L, Cacoub P, et al. Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology 1994;106:1291-300.
46. Delgado S, Bravo F, Gotuzzo E. Mixed cryoglobulinemia due to brucellosis. Clin Infect Dis 2008;47:435-6.
47. Padrón Romero M, Acevedo Ribó MM, Ahijado Hormigos FJ, et al. Membranoproliferative glomerulonephritis and mixed cryoglobulinemia as a form of presentation of visceral leishmaniasis. Am J Case Rep 2020;21:e921445.
48. Arora S, Levitan D, Regmi N, et al. Cryoglobulinemia in a patient with chronic lymphocytic leukemia - a case report and review of literature of renal involvement in CLL. Blood Cells Mol Dis 2016;60:7-11.
49. Lenzi M, Frisoni M, Mantovani V, et al. Haplotype HLA-B8-DR3 confers susceptibility to hepatitis C virus-related mixed cryoglobulinemia. Blood 1998;91:2062-6.
50. Zignego AL, Wojcik GL, Cacoub P, et al. Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis. Genes Immun 2014;15:500-5.
51. Gragnani L, Fognani E, Piluso A, Zignego AL. Hepatitis C virus-related mixed cryoglobulinemia: is genetics to blame? World J Gastroenterol 2013;19:8910-5.
52. De Re V, Caggiari L, De Zorzi M, et al. Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases. PLoS One 2015;10:e0117420.
53. Chang ML, Chang SW, Chen SC, et al. Genetic association of hepatitis C-related mixed cryoglobulinemia: a 10-year prospective study of asians treated with antivirals. Viruses 2021;13:464.
54. Crowley JJ, Goldfien RD, Schrohenloher RE, et al. Incidence of three cross-reactive idiotypes on human rheumatoid factor paraproteins. J Immunol 1988;140:3411-8.
55. Kunkel HG, Agnello V, Joslin FG, Winchester RJ, Capra JD. Cross-idiotypic specificity among monoclonal IgM proteins with anti- -globulin activity. J Exp Med 1973;137:331-42.
56. Shokri F, Mageed RA, Maziak BR, et al. Lymphoproliferation in primary Sjögren's syndrome. Evidence of selective expansion of a B cell subset characterized by the expression of cross-reactive idiotypes. Arthritis Rheum 1993;36:1128-36.
57. Tzioufas AG, Boumba DS, Skopouli FN, Moutsopoulos HM. Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome. Arthritis Rheum 1996;39:767-72.
58. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000;102:553-63.
59. De Vita S, De Re V, Sansonno D, et al. Gastric mucosa as an additional extrahepatic localization of hepatitis C virus: viral detection in gastric low-grade lymphoma associated with autoimmune disease and in chronic gastritis. Hepatology 2000;31:182-9.
60. Isnardi I, Ng YS, Menard L, et al. Complement receptor 2/CD21- human naive B cells contain mostly autoreactive unresponsive clones. Blood 2010;115:5026-36.
61. Ivanovski M, Silvestri F, Pozzato G, et al. Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood 1998;91:2433-42.
62. Flint M, Thomas JM, Maidens CM, et al. Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. J Virol 1999;73:6782-90.
63. Yagnik AT, Lahm A, Meola A, et al. A model for the hepatitis C virus envelope glycoprotein E2. Proteins 2000;40:355-66.
64. Sene D, Ghillani-Dalbin P, Thibault V, et al. Longterm course of mixed cryoglobulinemia in patients infected with hepatitis C virus. J Rheumatol 2004;31:2199-206.
65. Sansonno D, Cornacchiulo V, Iacobelli AR, Gatti P, Distasi M, Dammacco F. Hepatitis C virus infection and clonal B-cell expansion. Clin Exp Rheumatol 1996;14:S45-50.
66. Couronné L, Bachy E, Roulland S, et al. From hepatitis C virus infection to B-cell lymphoma. Ann Oncol 2018;29:92-100.
67. Agnello V, Zhang QX, Abel G, Knight GB. The association of hepatitis C virus infection with monoclonal rheumatoid factors bearing the WA cross-idiotype: implications for the etiopathogenesis and therapy of mixed cryoglobulinemia. Clin Exp Rheumatol 1995;13:S101-4.
68. Dammacco F, Sansonno D. Mixed cryoglobulinemia as a model of systemic vasculitis. Clin Rev Allergy Immunol 1997;15:97-119.
69. Agnello V. The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection. Springer Semin Immunopathol 1997;19:111-29.
70. Charles ED, Green RM, Marukian S, et al. Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia. Blood 2008;111:1344-56.
71. Perkins GB, Kim J, Coates PT. Going rogue: how autoantibodies become pathogenic. Kidney Int 2021;99:800-2.
72. Singh M, Jackson KJL, Wang JJ, et al. Lymphoma driver mutations in the pathogenic evolution of an iconic human autoantibody. Cell 2020;180:878-94.
73. Dustin LB, Rice CM. Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol 2007;25:71-99.
75. Alba MA, Jennette JC, Falk RJ. Chapter 65 - necrotizing arteritis and small-vessel vasculitis. In: Rose NR, Mackay IR, editors. The autoimmune diseases. Cambridge: Academic Press; 2020, pp. 1285-311.
76. Kolopp-Sarda MN, Miossec P. Cryoglobulinemic vasculitis: pathophysiological mechanisms and diagnosis. Curr Opin Rheumatol 2021;33:1-7.
77. Hall CG, Abraham GN. Reversible self-association of a human myeloma protein. Thermodynamics and relevance to viscosity effects and solubility. Biochemistry 1984;23:5123-9.
78. Kochwa S, Smith E, Brownell M, Wasserman LR. Aggregation of IgG globulin in vivo. II. Physicochemical properties of the isolated protein. Biochemistry 1966;5:277-85.
79. Erickson BW, Gerber-Jenson B, Wang AC, Litman GW. Molecular basis for the temperature-dependent insolubility of cryoglobulins - XI. Sequence comparison of the heavy-chain variable regions of the human cryoimmunoglobulins McE and Hil by metric analysis. Mol Immunol 1982;19:357-65.
80. Gerber-Jenson B, Kazin A, Kehoe JM, Scheffel C, Erickson BW, Litman GW. Molecular basis for the temperature-dependent insolubility of cryoglobulins. X. The amino acid sequence of the heavy chain variable region of McE. J Immunol 1981;126:1212-6.
81. Zinneman HH, Fromke VL, Seal US. Some biochemical properties of a cryomacroglobulin. Clin Chim Acta 1973;43:91-9.
82. Konieczny L, Bobrzecka K. Agreggation and precipitation in cryoglobulin. Bull Soc Chim Biol 1970;52:365-76.
83. Middaugh CR, Gerber-Jenson B, Hurvitz A, Paluszek A, Scheffel C, Litman GW. Physicochemical characterization of six monoclonal cryoimmunoglobulins: possible basis for cold-dependent insolubility. Proc Natl Acad Sci USA 1978;75:3440-4.
84. Andersen BR, Tesar JT, Schmid FR, Haisty WK, Hartz WH, Jr. Biological and physical properties of a human m-cryoglobulin and its monomer subunit. Clin Exp Immunol 1971;9:795-807.
85. Ramos-Casals M, Trejo O, García-Carrasco M, Cervera R, Font J. Mixed cryoglobulinemia: new concepts. Lupus 2000;9:83-91.
86. Lawson EQ, Brandau DT, Trautman PA, Aziz SE, Middaugh CR. Kinetics of the precipitation of cryoimmunoglobulins. Mol Immunol 1987;24:897-905.
87. Scoville CD, Turner DH, Lippert JL, Abraham GN. Study of the kinetic and structural properties of a monoclonal immunoglobulin G cryoglobulin. J Biol Chem 1980;255:5847-52.
88. Wang Y, Lomakin A, Hideshima T, et al. Pathological crystallization of human immunoglobulins. Proc Natl Acad Sci USA 2012;109:13359-61.
89. Podell DN, Packman CH, Maniloff J, Abraham GN. Characterization of monoclonal IgG cryoglobulins: fine-structural and morphological analysis. Blood 1987;69:677-81.
90. Vallas V, Farrugia W, Raison RL, Edmundson AB, Ramsland PA. Dissimilar aggregation processes govern precipitation and gelation of human IgM cryoglobulins. J Mol Recognit 2007;20:90-6.
91. Brandau DT, Trautman PA, Steadman BL, Lawson EQ, Middaugh CR. The temperature-dependent stoichiometry of mixed cryoimmunoglobulins. J Biol Chem 1986;261:16385-91.
92. Ng YC, Schifferli JA. Clearance of cryoglobulins in man. Springer Semin Immunopathol 1988;10:75-89.
94. Sansonno D, Tucci FA, Ghebrehiwet B, et al. Role of the receptor for the globular domain of C1q protein in the pathogenesis of hepatitis C virus-related cryoglobulin vascular damage. J Immunol 2009;183:6013-20.
95. Menegatti E, Messina M, Oddone V, et al. Immunogenetics of complement in mixed cryoglobulinaemia. Clin Exp Rheumatol 2016;34:S12-5.
96. Karras A, Noël LH, Droz D, et al. Renal involvement in monoclonal (type I) cryoglobulinemia: two cases associated with IgG3 kappa cryoglobulin. Am J Kidney Dis 2002;40:1091-6.
97. Zaidan M, Terrier B, Pozdzik A, et al. CryoVas study group. Spectrum and prognosis of noninfectious renal mixed cryoglobulinemic GN. J Am Soc Nephrol 2016;27:1213-24.
98. Nasr SH, Markowitz GS, Reddy BS, Maesaka J, Swidler MA, D'Agati VD. Dysproteinemia, proteinuria, and glomerulonephritis. Kidney Int 2006;69:772-5.
99. Rother U, Rother K, Flad HD, Miescher PA. Bithermic complement activation in cryoglobulinaemic serum. Eur J Clin Invest 1972;2:59-65.
100. Linscott WD, Kane JP. The complement system in cryoglobulinaemia. Interaction with immunoglobulins and lipoproteins. Clin Exp Immunol 1975;21:510-9.
101. Naish PF, Collins C, Barratt J. Classical pathway complement activation in association with paraproteinaemia. Immunology 1977;33:517-21.
102. Stasio E, Bizzarri P, Casato M, Galtieri A, Fiorilli M, Pucillo LP. Cl- regulates cryoglobulin structure: a new hypothesis for the physiopathological mechanism of temperature non-dependent cryoprecipitation. Clin Chem Lab Med 2004;42:614-20.
103. Di Stasio E, Bizzarri P, Bove M, et al. Analysis of the dynamics of cryoaggregation by light-scattering spectrometry. Clin Chem Lab Med 2003;41:152-8.
104. Strait RT, Posgai MT, Mahler A, et al. IgG1 protects against renal disease in a mouse model of cryoglobulinaemia. Nature 2015;517:501-4.
105. Sargur R, White P, Egner W. Cryoglobulin evaluation: best practice? Ann Clin Biochem 2010;47:8-16.
107. Qi M, Steiger G, Schifferli JA. A calcium-dependent cryoglobulin IgM kappa/polyclonal IgG. J Immunol 1992;149:2345-51.
108. Rosa FG, Agnello V. Observations on cryoglobulin testing: I. The association of cryoglobulins containing rheumatoid factors with manifestation of cryoglobulinemic vasculitis. J Rheumatol 2009;36:1953-5.
109. Garcia-Bragado F, Fernandez JM, Navarro C, Villar M, Bonaventura I. Peripheral neuropathy in essential mixed cryoglobulinemia. Arch Neurol 1988;45:1210-4.
110. Tredici G, Petruccioli MG, Cavaletti G, Marmiroli P, Crespi V, Pioltelli P. Sural nerve bioptic findings in essential cryoglobulinemic patients with and without peripheral neuropathy. Clin Neuropathol 1992;11:121-7.
111. Cavaletti G, Petruccioli MG, Crespi V, Pioltelli P, Marmiroli P, Tredici G. A clinico-pathological and follow up study of 10 cases of essential type II cryoglobulinaemic neuropathy. J Neurol Neurosurg Psychiatry 1990;53:886-9.
113. Cacoub P, Comarmond C, Domont F, Savey L, Saadoun D. Cryoglobulinemia vasculitis. Am J Med 2015;128:950-5.
114. D'Amico G, Colasanti G, Ferrario F, Sinico RA. Renal involvement in essential mixed cryoglobulinemia. Kidney Int 1989;35:1004-14.
115. Javaugue V, Valeri AM, Jaffer Sathick I, et al. The characteristics of seronegative and seropositive non-hepatitis-associated cryoglobulinemic glomerulonephritis. Kidney Int 2022;102:382-94.
116. Beddhu S, Bastacky S, Johnson JP. The clinical and morphologic spectrum of renal cryoglobulinemia. Medicine 2002;81:398-409.
117. Sinico RA, Winearls CG, Sabadini E, Fornasieri A, Castiglione A, D'Amico G. Identification of glomerular immune deposits in cryoglobulinemia glomerulonephritis. Kidney Int 1988;34:109-16.
119. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. Arthritis Rheum 1999;42:2204-12.
120. Dammacco R, Lisch W, Kivelä TT, et al. The spectrum of ocular manifestations in patients with Waldenström's macroglobulinemia. Ocul Immunol Inflamm 2022;30:1659-68.
121. Terrier B, Krastinova E, Marie I, et al. Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood 2012;119:5996-6004.
122. Wener MH, Hutchinson K, Morishima C, Gretch DR. Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia. Arthritis Rheum 2004;50:2305-8.
123. Ferri C, Ramos-Casals M, Zignego AL, et al. ISG-EHCV coauthors. International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun Rev 2016;15:1145-60.
124. Ferri C, Sebastiani M, Giuggioli D, et al. Hepatitis C virus syndrome: a constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin's lymphoma, and cancer. World J Hepatol 2015;7:327-43.
125. Giuggioli D, Manfredi A, Lumetti F, Sebastiani M, Ferri C. Cryoglobulinemic vasculitis and skin ulcers. Our therapeutic strategy and review of the literature. Semin Arthritis Rheum 2015;44:518-26.
126. Gorevic PD, Kassab HJ, Levo Y, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med 1980;69:287-308.
127. Monti G, Galli M, Invernizzi F, et al. Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. QJM 1995;88:115-26.
128. Sansonno D, Dammacco F. Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. Lancet Infect Dis 2005;5:227-36.
130. De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012;64:843-53.
131. Zaltron S, Puoti M, Liberini P, et al. High prevalence of peripheral neuropathy in hepatitis C virus infected patients with symptomatic and asymptomatic cryoglobulinaemia. Ital J Gastroenterol Hepatol 1998;30:391-5.
132. Gemignani F, Brindani F, Alfieri S, et al. Clinical spectrum of cryoglobulinaemic neuropathy. J Neurol Neurosurg Psychiatry 2005;76:1410-4.
133. Ferri C, La Civita L, Cirafisi C, et al. Peripheral neuropathy in mixed cryoglobulinemia: clinical and electrophysiologic investigations. J Rheumatol 1992;19:889-95.
134. Feldman L, Dhamne M, Li Y. Neurologic manifestations associated with cryoglobulinemia: a single center experience. J Neurol Sci 2019;398:121-7.
135. Rossi D, Sciascia S, Fenoglio R, et al. Cryoglobulinemic glomerulonephritis: clinical presentation and histological features, diagnostic pitfalls and controversies in the management. State of the art and the experience on a large monocentric cohort treated with B cell depletion therapy. Minerva Med 2021;112:162-74.
136. Matignon M, Cacoub P, Colombat M, et al. Clinical and morphologic spectrum of renal involvement in patients with mixed cryoglobulinemia without evidence of hepatitis C virus infection. Medicine 2009;88:341-8.
137. Coliche V, Sarda MN, Laville M, et al. Predictive factors of renal involvement in cryoglobulinaemia: a retrospective study of 153 patients. Clin Kidney J 2019;12:365-72.
138. Tarantino A, Campise M, Banfi G, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995;47:618-23.
139. Roccatello D, Fornasieri A, Giachino O, et al. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 2007;49:69-82.
140. Usuda H, Emura I, Naito M. Crystalglobulin-induced vasculopathy accompanying ischemic intestinal lesions of a patient with myeloma. Pathol Int 1996;46:165-70.
141. Terrier B, Karras A, Cluzel P, et al. Presentation and prognosis of cardiac involvement in hepatitis C virus-related vasculitis. Am J Cardiol 2013;111:265-72.
142. Ali MA, Kayani WZ, Linzie BM, Punjabi GV, Wetmore JB. Myopericarditis in a patient with hepatitis C and cryoglobulinemic renal disease. Clin Case Rep 2017;5:616-20.
143. Amital H, Rubinow A, Naparstek Y. Alveolar hemorrhage in cryoglobulinemia - an indicator of poor prognosis. Clin Exp Rheumatol 2005;23:616-20.
144. Zackrison LH, Katz P. Bronchiolitis obliterans organizing pneumonia associated with essential mixed cryoglobulinemia. Arthritis Rheum 1993;36:1627-30.
145. Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology 2016;150:1599-608.
146. Ramos-Casals M, Robles A, Brito-Zerón P, et al. Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases. Semin Arthritis Rheum 2006;36:189-96.
147. Galli M, Monti G, Marson P, et al. Recommendations for managing the manifestations of severe and life-threatening mixed cryoglobulinemia syndrome. Autoimmun Rev 2019;18:778-85.
148. Fermand JP, Bridoux F, Dispenzieri A, et al. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood 2018;132:1478-85.
149. Besada E, Vik A, Koldingsnes W, Nossent JC. Successful treatment with bortezomib in type-1 cryoglobulinemic vasculitis patient after rituximab failure: a case report and literature review. Int J Hematol 2013;97:800-3.
150. Payet J, Livartowski J, Kavian N, et al. Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature. Leuk Lymphoma 2013;54:767-77.
151. Calabrese C, Faiman B, Martin D, Reu F, Calabrese LH. Type 1 cryoglobulinemia: response to thalidomide and lenalidomide. J Clin Rheumatol 2011;17:145-7.
152. Lin RJ, Curran JJ, Zimmerman TM, Song J, Niewold TB, Sweiss NJ. Lenalidomide for the treatment of cryoglobulinemia and undifferentiated spondyloarthropathy in a patient with multiple myeloma. J Clin Rheumatol 2010;16:90-1.
153. Leung N, Bridoux F, Hutchison CA, et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 2012;120:4292-5.
154. Bridoux F, Leung N, Hutchison CA, et al. International Kidney and Monoclonal Gammopathy Research Group. Diagnosis of monoclonal gammopathy of renal significance. Kidney Int 2015;87:698-711.
155. Leung N, Bridoux F, Batuman V, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol 2019;15:45-59.
156. Fermand JP, Bridoux F, Kyle RA, et al. International Kidney and Monoclonal Gammopathy Research Group. How I treat monoclonal gammopathy of renal significance (MGRS). Blood 2013;122:3583-90.
157. Motwani SS, Herlitz L, Monga D, Jhaveri KD, Lam AQ. American Society of Nephrology Onco-Nephrology Forum. Paraprotein-related kidney disease: glomerular diseases associated with paraproteinemias. Clin J Am Soc Nephrol 2016;11:2260-72.
158. Dimopoulos MA, Oriol A, Nahi H, et al. POLLUX Investigators. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016;375:1319-31.
159. Milani P, Basset M, Curci P, et al. Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function. Blood Adv 2020;4:1321-4.
160. Kastritis E, Theodorakakou F, Roussou M, et al. Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance. Br J Haematol 2021;193:113-8.
161. Sethi S, Fervenza FC, Rajkumar SV. Spectrum of manifestations of monoclonal gammopathy-associated renal lesions. Curr Opin Nephrol Hypertens 2016;25:127-37.
162. Talamo G, Claxton D, Tricot G, Fink L, Zangari M. Response to bortezomib in refractory type I cryoglobulinemia. Am J Hematol 2008;83:883-4.
163. Spizzo G, Mitterer M, Gunsilius E. Bortezomib for the treatment of refractory type-1 cryoglobulinaemia. Br J Haematol 2010;150:235-7.
164. Ramirez GA, Campochiaro C, Salmaggi C, et al. Bortezomib in type I cryoglobulinemic vasculitis: are we acting too late? Intern Med 2015;54:1119-23.
165. Ar M, Soysal T, Hatemi G, Salihoglu A, Yazici H, Ulku B. Successful management of cryoglobulinemia-induced leukocytoclastic vasculitis with thalidomide in a patient with multiple myeloma. Ann Hematol 2005;84:609-13.
166. Sampson A, Callen JP. The cutting edge: thalidomide for type 1 cryoglobulinemic vasculopathy. Arch Dermatol 2006;142:972-4.
167. Callander NS, Baljevic M, Adekola K, et al. NCCN guidelines® insights: multiple myeloma, version 3. J Natl Compr Canc Netw 2022;20:8-19.
168. Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Ann Oncol 2021;32:309-22.
169. Castillo JJ, Advani RH, Branagan AR, et al. Consensus treatment recommendations from the tenth international workshop for waldenström macroglobulinaemia. Lancet Haematol 2020;7:e827-37.
170. Terpos E, Mikhael J, Hajek R, et al. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer J 2021;11:40.
171. Moreau P, Kumar SK, San Miguel J, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol 2021;22:e105-18.
172. Chu D, Stevens M, Gladstone DE. Severe, refractory, non-malignant type I cryoglobulinemia treated with alemtuzumab. Rheumatol Int 2007;27:1173-5.
173. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007;25:3344-9.
174. Dimopoulos MA, García-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European myeloma network (EMN). Blood 2013;122:3276-82.
175. Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenstrom's macroglobulinemia. N Engl J Med 2018;378:2399-410.
176. Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the Eighth International Workshop on Waldenström's macroglobulinemia. Blood 2016;128:1321-8.
177. Gertz MA. Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012;87:503-10.
178. Saadoun D, Pineton de Chambrun M, Hermine O, et al. Using rituximab plus fludarabine and cyclophosphamide as a treatment for refractory mixed cryoglobulinemia associated with lymphoma. Arthritis Care Res 2013;65:643-7.
179. Perez-Alamino R, Espinoza LR. Non-infectious cryoglobulinemia vasculitis (CryoVas): update on clinical and therapeutic approach. Curr Rheumatol Rep 2014;16:420.
180. Martin M, Lipsker D, Fornecker LM, Toussaint E, Martin T. Bendamustine conditioning for refractory type I cryoglobulinemia. Joint Bone Spine 2016;83:591-2.
181. Tedeschi A, Conticello C, Rizzi R, et al. Diagnostic framing of IgM monoclonal gammopathy: focus on Waldenström macroglobulinemia. Hematol Oncol 2019;37:117-28.
182. Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med 2015;372:1430-40.
183. Ghobrial IM, Witzig TE, Gertz M, et al. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. Am J Hematol 2014;89:237-42.
184. Treon SP, Tripsas CK, Meid K, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. Blood 2014;124:503-10.
185. Treon SP, Soumerai JD, Branagan AR, et al. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008;112:4452-7.
186. Hunter ZR, Xu L, Yang G, et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 2014;123:1637-46.
187. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med 2012;367:826-33.
188. Goglin S, Chung SA. Current treatment of cryoglobulinemic vasculitis. Curr Treat Options Rheum 2016;2:213-24.
189. Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American society for apheresis: the eighth special issue. J Clin Apher 2019;34:171-354.
190. Yang CH, Qureshi AA, Churchill WH, Saavedra AP. Long-term plasmapheresis in conjunction with thalidomide and dexamethasone for the treatment of cutaneous ulcers and neovascular glaucoma in recalcitrant type I cryoglobulinemia. JAMA Dermatol 2014;150:426-8.
191. Nehme-Schuster H, Korganow AS, Pasquali JL, Martin T. Rituximab inefficiency during type I cryoglobulinaemia. Rheumatology 2005;44:410-1.
192. Ghobrial IM, Fonseca R, Greipp PR, et al. Eastern Cooperative Oncology Group. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern cooperative oncology group study. Cancer 2004;101:2593-8.
193. Treon SP, Branagan AR, Hunter Z, Santos D, Tournhilac O, Anderson KC. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol 2004;15:1481-3.
194. Shaikh A, Habermann TM, Fidler ME, Kumar S, Leung N. Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenström's macroglobulinemia. Clin Exp Nephrol 2008;12:292-5.
195. Mazzi G, Raineri A, Zucco M, Passadore P, Pomes A, Orazi BM. Plasma-exchange in chronic peripheral neurological disorders. Int J Artif Organs 1999;22:40-6.
196. Sinico RA, Fornasieri A, Fiorini G, et al. Plasma exchange in the treatment of essential mixed cryoglobulinemia nephropathy. Long-term follow up. Int J Artif Organs 1985;8 Suppl 2:15-8.
197. L'Abbate A, Maggiore Q, Caccamo A, et al. Long term effects of cryoapheresis and cytostatic treatment in essential mixed cryoglobulinemia. Int J Artif Organs 1985;8:19-22.
198. Rockx MA, Clark WF. Plasma exchange for treating cryoglobulinemia: a descriptive analysis. Transfus Apher Sci 2010;42:247-51.
199. Guillevin L, Pagnoux C. Indications of plasma exchanges for systemic vasculitides. Ther Apher Dial 2003;7:155-60.
200. Stone MJ, Bogen SA. Evidence-based focused review of management of hyperviscosity syndrome. Blood 2012;119:2205-8.
201. Stone MJ. Waldenström's macroglobulinemia: hyperviscosity syndrome and cryoglobulinemia. Clin Lymphoma Myeloma 2009;9:97-9.
203. Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB. Italian Association of the Study of Liver Commission on Extrahepatic Manifestations of HCV infection. Extrahepatic manifestations of hepatitis C virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis 2007;39:2-17.
204. Pouchelon C, Visentini M, Emmi G, et al. Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: data from a European collaborative study and review of the literature. Autoimmun Rev 2022;21:103034.
205. Dammacco F, Lauletta G, Russi S, et al. Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis. Clin Exp Med 2019;19:1-21.
206. Monti G, Saccardo F, Rinaldi G, Petrozzino MR, Gomitoni A, Invernizzi F. Colchicine in the treatment of mixed cryoglobulinemia. Clin Exp Rheumatol 1995;13:S197-9.
207. Ferri C, Cacoub P, Mazzaro C, et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev 2011;11:48-55.
208. Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 2012;64:835-42.
209. Specks U, Merkel PA, Seo P, et al. RAVE-ITN Research Group. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013;369:417-27.
210. Zaja F, Russo D, Fuga G, et al. Rituximab for the treatment of type II mixed cryoglobulinemia. Haematologica 2002;46:2252-64.
211. Arzoo K, Sadeghi S, Liebman HA. Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 2002;61:922-4.
212. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003;101:3818-26.
213. Vita S, Quartuccio L, Fabris M. Rituximab in mixed cryoglobulinemia: increased experience and perspectives. Dig Liver Dis 2007;39:S122-8.
214. Cavallo R, Roccatello D, Menegatti E, Naretto C, Napoli F, Baldovino S. Rituximab in cryoglobulinemic peripheral neuropathy. J Neurol 2009;256:1076-82.
215. Dammacco F, Tucci FA, Lauletta G, et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 2010;116:343-53.
216. Petrarca A, Rigacci L, Caini P, et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 2010;116:335-42.
217. Quartuccio L, Petrarca A, Mansutti E, et al. Efficacy of rituximab in severe and mild abdominal vasculitis in the course of mixed cryoglobulinemia. Clin Exp Rheumatol 2010;28:84-7.
218. Quartuccio L, Soardo G, Romano G, et al. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Rheumatology 2006;45:842-6.
219. Roccatello D, Baldovino S, Rossi D, et al. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. Clin Rev Allergy Immunol 2008;34:111-7.
220. Roccatello D, Baldovino S, Rossi D, et al. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004;19:3054-61.
221. Saadoun D, Resche-Rigon M, Sene D, Perard L, Karras A, Cacoub P. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Ann Rheum Dis 2008;67:1431-6.
222. Terrier B, Launay D, Kaplanski G, et al. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French autoimmunity and rituximab registry. Arthritis Care Res 2010;62:1787-95.
223. Visentini M, Ludovisi S, Petrarca A, et al. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmun Rev 2011;10:714-9.
224. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003;101:3827-34.
225. Visentini M, Granata M, Veneziano ML, et al. Efficacy of low-dose rituximab for mixed cryoglobulinemia. Clin Immunol 2007;125:30-3.
226. Roccatello D, Sciascia S, Baldovino S, et al. Improved (4 Plus 2) Rituximab protocol for severe cases of mixed cryoglobulinemia: a 6-year observational study. Am J Nephrol 2016;43:251-60.
227. Bryce AH, Dispenzieri A, Kyle RA, et al. Response to rituximab in patients with type II cryoglobulinemia. Clin Lymphoma Myeloma 2006;7:140-4.
228. Wink F, Houtman PM, Jansen TL. Rituximab in cryoglobulinaemic vasculitis, evidence for its effectivity: a case report and review of literature. Clin Rheumatol 2011;30:293-300.
229. Terrier B, Marie I, Launay D, et al. Predictors of early relapse in patients with non-infectious mixed cryoglobulinemia vasculitis: results from the French nationwide CryoVas survey. Autoimmun Rev 2014;13:630-4.
230. Visentini M, Tinelli C, Colantuono S, et al. Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review. Autoimmun Rev 2015;14:889-96.
231. Foessel L, Besancenot JF, Blaison G, et al. Clinical spectrum, treatment, and outcome of patients with type II mixed cryoglobulinemia without evidence of hepatitis C infection. J Rheumatol 2011;38:716-22.
232. Terrier B, Saadoun D, Sène D, et al. Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: a long-term followup study of thirty-two patients. Arthritis Rheum 2009;60:2531-40.
233. Zignego AL, Ramos-Casals M, Ferri C, et al. ISG-EHCV. International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. Autoimmun Rev 2017;16:523-41.
234. Ramos-Casals M, Zignego AL, Ferri C, et al. International Study Group of Extrahepatic Manifestations related to HCV (ISG-EHCV). Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. J Hepatol 2017;66:1282-99.
235. Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American society for apheresis: the seventh special issue. J Clin Apher 2016;31:149-338.
236. Naciri Bennani H, Banza AT, Terrec F, et al. Cryoglobulinemia and double-filtration plasmapheresis: Personal experience and literature review. Ther Apher Dial 2023;27:159-69.
237. Evans TW, Nicholls AJ, Shortland JR, Ward AM, Brown CB. Acute renal failure in essential mixed cryoglobulinemia: precipitation and reversal by plasma exchange. Clin Nephrol 1984;21:287-93.
238. Puisset F, White-Koning M, Kamar N, et al. Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease. Br J Clin Pharmacol 2013;76:734-40.
239. Ramos-Casals M, Font J. Extrahepatic manifestations in patients with chronic hepatitis C virus infection. Curr Opin Rheumatol 2005;17:447-55.
240. Mukhtyar C, Guillevin L, Cid MC, et al. European Vasculitis Study Group. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009;68:310-7.
241. Argyropoulou OD, Pezoulas V, Chatzis L, et al. Cryoglobulinemic vasculitis in primary Sjögren's syndrome: clinical presentation, association with lymphoma and comparison with hepatitis C-related disease. Semin Arthritis Rheum 2020;50:846-53.
242. Basse G, Ribes D, Kamar N, et al. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation 2005;80:1560-4.
243. Cacoub P, Delluc A, Saadoun D, Landau DA, Sene D. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis 2008;67:283-7.
244. Basile U, Gulli F, Napodano C, et al. Biomarkers of minimal residual disease in rituximab-treated patients with mixed cryoglobulinemia. Biotechnol Appl Biochem 2021;68:319-29.
245. Frankel AH, Singer DR, Winearls CG, Evans DJ, Rees AJ, Pusey CD. Type II essential mixed cryoglobulinaemia: presentation, treatment and outcome in 13 patients. Q J Med 1992;82:101-24.
246. Verdickt W, Dequeker J. Plasmapheresis combined with corticosteroids and cyclophosphamide in mixed monoclonal cryoglobulinaemia. Acta Clin Belg 1982;37:237-40.
247. McKenzie RG, Anavekar SN, Dawborn JK, et al. Glomerulonephritis secondary to mixed polyclonal cryoglobulinaemia: response to immunosuppression and plasmapheresis. Aust N Z J Med 1981;11:529-33.
248. Geltner D, Kohn RW, Gorevic P, Franklin EC. The effect of combination therapy (steroids, immunosuppressives, and plasmapheresis) on 5 mixed cryoglobulinemia patients with renal, neurologic, and vascular involvement. Arthritis Rheum 1981;24:1121-7.
249. Houwert DA, Hene RJ, Struyvenberg A, Kater L. Effect of plasmapheresis (PP), corticosteroids and cyclophosphamide in essential mixed polyclonal cryoglobulinaemia associated with glomerulonephritis. Proc Eur Dial Transplant Assoc 1980;17:650-4.
250. Ferri C, Moriconi L, Gremignai G, et al. Treatment of the renal involvement in mixed cryoglobulinemia with prolonged plasma exchange. Nephron 1986;43:246-53.
251. Bombardieri S, Ferri C, Paleologo G, et al. Prolonged plasma exchange in the treatment of renal involvement in essential mixed cryoglobulinemia. Int J Artif Organs 1983;6:47-50.
252. Ramunni A, Lauletta G, Brescia P, et al. Double-filtration plasmapheresis in the treatment of leg ulcers in cryoglobulinemia. J Clin Apher 2008;23:118-22.
253. Auzerie V, Chiali A, Bussel A, et al. Leg ulcers associated with cryoglobulinemia: clinical study of 15 patients and response to treatment. Arch Dermatol 2003;139:391-3.
254. Chevalier K, Belkhir R, Seror R, Mariette X, Nocturne G. Efficacity of a sequential treatment by anti-CD 20 monoclonal antibody and belimumab in type II cryoglobulinaemia associated with primary Sjögren syndrome refractory to rituximab alone. Ann Rheum Dis 2020;79:1257-9.
255. Saadoun D, Ghembaza A, Riviere S, et al. Rituximab plus belimumab in non-infectious refractory cryoglobulinemia vasculitis: a pilot study. J Autoimmun 2021;116:102577.
256. De Vita S, Quartuccio L, Salvin S, et al. Sequential therapy with belimumab followed by rituximab in Sjogren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy. Clin Exp Rheumatol 2014;32:490-4.
257. Cohen C, Mekinian A, Saidenberg-Kermanac'h N, et al. Efficacy of tocilizumab in rituximab-refractory cryoglobulinemia vasculitis. Ann Rheum Dis 2012;71:628-9.
258. Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011;365:2067-77.
259. Genest DS, Pelletier K, Dallaire G, Faucher G, Troyanov S. Obinutuzumab rescue in rituximab resistant mixed cryoglobulinemia. Kidney Int Rep 2021;6:865-6.
260. Dutton K, Savic S, Owen R, Vital E. Resistant type II cryoglobulinaemic vasculitis successfully treated with bortezomib in a patient with SLE. BMJ Case Rep 2019;12:e226083.
261. Castillo JJ, Kanan S, Meid K, Manning R, Hunter ZR, Treon SP. Rituximab intolerance in patients with Waldenström macroglobulinaemia. Br J Haematol 2016;174:645-8.
262. Ostojic P. Cryoglobulinemic vasculitis in systemic sclerosis successfully treated with mycophenolate mofetil. Rheumatol Int 2014;34:145-7.
263. Desbois AC, Biard L, Sène D, et al. Rituximab-associated vasculitis flare: incidence, predictors, and outcome. J Rheumatol 2020;47:896-902.
264. Li X, Lin Q, Dong M, et al. Prognostic analysis of acute exacerbations of hepatitis-B after chemotherapy in combination with rituximab in 19 patients with lymphoma. Leuk Lymphoma 2010;51:1678-85.
265. Marignani M, Mangone M, Cox MC, et al. HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens. Dig Liver Dis 2011;43:139-42.
266. Sy-Go JPT, Thongprayoon C, Herrera Hernandez LP, Zoghby Z, Leung N, Manohar S. Rituximab-associated flare of cryoglobulinemic vasculitis. Kidney Int Rep 2021;6:2840-9.
267. Sène D, Ghillani-Dalbin P, Amoura Z, Musset L, Cacoub P. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum 2009;60:3848-55.
268. Bryce AH, Kyle RA, Dispenzieri A, Gertz MA. Natural history and therapy of 66 patients with mixed cryoglobulinemia. Am J Hematol 2006;81:511-8.
269. Terrier B, Carrat F, Krastinova E, et al. Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis: data from 242 cases included in the CryoVas survey. Ann Rheum Dis 2013;72:374-80.
270. Saadoun D, Sellam J, Ghillani-Dalbin P, Crecel R, Piette JC, Cacoub P. Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia. Arch Intern Med 2006;166:2101-8.
271. Landau DA, Scerra S, Sene D, Resche-Rigon M, Saadoun D, Cacoub P. Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy. J Rheumatol 2010;37:615-21.
272. Eble V, Legallicier B, Joly P, et al. Long term outcome of patients with low level of cryoglobulin (<0.05g/L). Autoimmun Rev 2016;15:440-6.
273. Invernizzi F, Pioltelli P, Cattaneo R, et al. A long-term follow-up study in essential cryoglobulinemia. Acta Haematol 1979;61:93-9.
274. Civita L, Zignego AL, Monti M, Longombardo G, Pasero G, Ferri C. Mixed cryoglobulinemia as a possible preneoplastic disorder. Arthritis Rheum 1995;38:1859-60.
275. Ramos-Casals M, Trejo O, Garcia-Carrasco M, et al. Triple association between hepatitis C virus infection, systemic autoimmune diseases, and B cell lymphoma. J Rheumatol 2004;31:495-9.
276. Monti G, Pioltelli P, Saccardo F, et al. Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Arch Intern Med 2005;165:101-5.
277. Saadoun D, Landau DA, Calabrese LH, Cacoub PP. Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation. Rheumatology 2007;46:1234-42.
278. Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 2007;297:2010-7.
279. Artemova M, Abdurakhmanov D, Ignatova T, Mukhin N. Persistent hepatitis C virus-associated cryoglobulinemic vasculitis following virus eradication after direct-acting antiviral therapy. Hepatology 2017;65:1770-1.
280. Sollima S, Milazzo L, Antinori S, Galli M. Direct-acting antivirals and mixed cryoglobulinemia vasculitis: long-term outcome of patients achieving HCV eradication. Am J Gastroenterol 2017;112:1753-4.
281. Saadoun D, Pol S, Ferfar Y, et al. Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis. Gastroenterology 2017;153:49-52.
282. Saadoun D, Resche-Rigon M, Thibault V, Piette JC, Cacoub P. Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum 2006;54:3696-706.
283. Bonacci M, Lens S, Mariño Z, et al. Long-term outcomes of patients with HCV-associated cryoglobulinemic vasculitis after virologic cure. Gastroenterology 2018;155:311-15.
284. Banerjee D, Reddy KR. Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Aliment Pharmacol Ther 2016;43:674-96.
285. Colantuono S, Marrapodi R, Del Padre M, et al. Clinico-immunological outcomes of HCV-cured cryoglobulinemia: lower relapse rate with interferon-based than interferon-free therapy. Liver Int 2021;41:70-5.
286. Scarpato S, Sebastiani M, Quartuccio L, et al. Italian Group for the Study of Cryoglobulinaemia (GISC). Provisional recommendations for SARS-CoV-2 vaccination in patients with cryoglobulinaemic vasculitis. Clin Exp Rheumatol 2021;39:149-54.
